Skip to main content
Fig. 10 | Translational Neurodegeneration

Fig. 10

From: Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease

Fig. 10

MiR-504-3p alleviates tau hyperphosphorylation by targeting p39. a, b N2a cells were transfected with NC or miR-504-3p mimics. The expression of pThr231 tau, pSer396 tau and total tau was examined. β-actin was used as an internal control. Data are presented as the means ± standard errors of three independent experiments (**P < 0.01 vs. the untreated group). c, d N2a cells were transfected with NC or a miR-504-3p inhibitor and then treated with melatonin. The expression of pThr231 tau, pSer396 tau and total tau was examined. β-actin was used as an internal control. The data are presented as the means ± standard errors of three independent experiments (**P < 0.01, ****P < 0.0001 vs. the group treated with melatonin alone). e, f N2a cells were cotransfected with NC or miR-504-3p mimics and a p39 plasmid (without a miR-504-3p-binding site) or vector. The protein levels of p39, pThr231 tau, pSer396 tau and total tau were measured using immunoblotting. Data are presented as the means ± standard errors of three independent experiments (*P < 0.05, **P < 0.01 vs. the group cotransfected with miR-504-3p mimics and vector)

Back to article page